ClinicalTrials.gg
CompletedNCT05065970IGNAZUpdated Apr 28, 2026Results posted

Clinical Trial to Assess Efficacy and Safety of the Human Anti-CD38 Antibody Felzartamab (MOR202) in IgA Nephropathy

A Phase 2 interventional study of Felzartamab and Placebo in Immunoglobulin A (IgA) Nephropathy, sponsored by HI-Bio, A Biogen Company. Completed at 59 sites in 15 countries. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-04-28.

Primary conditionGlomerulonephritis, IGARegistry: Kidney DiseasesReclassifiedWhy we changed it
Registry
Kidney Diseases — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glomerulonephritis, IGA
Why
  1. The study's title name Glomerulonephritis, IGA, a narrower term within Kidney Diseases.
Confidence
High: the new condition is named in the study's own title. Of 46 hand-checked studies reclassified this way, 72% were exactly right and 89% in the right disease family; the registry's first term was right for 4% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by HI-Bio, A Biogen Company (part of Biogen) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
54
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 22 studies in Glomerulonephritis, IGA with a site in Japan — 8 open to participants now, 15 under way, 12 of them phase 3. Glomerulonephritis, IGA · Japan.

Enrollment
15th of 22
54 · median 138
Started
2021
with 2 others
Phase 2
7 of 22
2 open now
Registered
9th of 22
by date
Lead sponsor
1 of 22
HI-Bio, A Biogen Company

Among the 22 studies in Glomerulonephritis, IGA with a site in Japan, this one is the 15th largest by enrollment, is one of 3 that started in 2021, is one of 7 in phase 2, and was the 9th registered.

Glomerulonephritis, IGA

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

Browse Glomerulonephritis, IGA studies →

Open to participants now

8 of the 22 studies in Glomerulonephritis, IGA with a site in Japan are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →

Who these studies take

Of the 68 Glomerulonephritis, IGA studies recruiting now, 39 (57%) set no upper age limit and 24 (35%) stop at 75 or younger; 21 take children under 18; 5 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 22 studies in Glomerulonephritis, IGA with a site in Japan, or all of them as a file.
02

Study summary

Randomized, placebo-controlled, multi-center, double-blind, proof of concept phase IIa trial and dose evaluation trial of felzartamab in IgAN

Read the detailed description

Study Sponsor, originally HI-Bio, Inc., is now HI-Bio, A Biogen Company.

03

Conditions studied

  • Immunoglobulin A (IgA) Nephropathy

Browse trials for

Keywords

  • Kidney Disease
  • Urologic Disease
  • Glomerular Disease
  • Berger Disease
  • Glomerulonephritis, IGA
04

In context

Glomerulonephritis, IGA Reclassified

276 studies on the registry are indexed under Glomerulonephritis, IGA; 108 are open to participants now.

This study's enrollment of 54 is below the median of 62 across 221 interventional studies indexed under Glomerulonephritis, IGA.

Browse Glomerulonephritis, IGA studies →

Lead sponsor

HI-Bio, A Biogen Company is the lead sponsor of 5 studies on the registry; none are open to participants now.

Of its 5 completed or terminated interventional studies of FDA-regulated products, 2 (40%) have results posted.

First submitted before HI-Bio became part of Biogen.

Compared within Glomerulonephritis, IGA, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Kidney Diseases. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Patients ≥ 18 to ≤ 80 years (at date of signing the form [ICF]), but at least of legal age in the given country
  • confirmed diagnosis of IgAN within the past 8 years prior to signature of the ICF
  • Proteinuria at screening visit ≥ 1.0 g/d.
  • Treatment with an angiotensin-converting enzyme inhibitor (ACEi) and/or angiotensin receptor blocker (ARB) at maximum doses or maximally tolerated doses for ≥ 3 months prior to date of informed consent and adequate blood pressure (BP) control.
  • A female of (FCBP), is only eligible to participate if she is not pregnant, not breast feeding, and agrees to follow the guidance during the treatment period and for at least 3 months after the last dose of IMP

Key Exclusion Criteria:

  • \< 90 g/L
  • Thrombocytopenia: \< 100.0 x 10\^9/L.
  • Neutropenia: Neutrophils \< 1.5 x 10\^9/L.
  • Leukopenia: Leukocytes \< 3.0 x 10\^9/L
  • Diabetes mellitus type 1
  • or alanine aminotransferase >1.5 x , alkaline phosphatase >3.0 x ULN
Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
54 participants (actual)

Study arms

  • Placebo comparator
    Part 1: Placebo

    Participants were administered felzartamab matching placebo as an intravenous (IV) infusion on Days 1, 8, 15, 22, 29, 57, 85, 113 and 141.

    Other: Placebo

  • Experimental
    Part 1: Felzartamab Dosing Arm M1

    Participants were administered felzartamab as an IV infusion based on their body weight on Days 1 and 15, and felzartamab matching placebo on Days 8, 22, 29, 57, 85, 113 and 141.

    Drug: Felzartamab · Other: Placebo

  • Experimental
    Part 1: Felzartamab Dosing Arm M2

    Participants were administered felzartamab as an IV infusion based on their body weight on Days 1, 8,15, 29, and 57, and felzartamab matching placebo on Days 22, 85, 113 and 141.

    Drug: Felzartamab · Other: Placebo

  • Experimental
    Part 1: Felzartamab Dosing Arm M3

    Participants were administered felzartamab as an IV infusion based on their body weight on Days 1,8,15, 22, 29, 57, 85, 113 and 141.

    Drug: Felzartamab

  • Experimental
    Part 2: Japan Cohort

    Japanese participants were administered felzartamab as an IV infusion based on their body weight on Days 1,8,15, 22, 29, 57, 85, 113 and 141.

    Drug: Felzartamab

Interventions

  • anti-CD38+ monoclonal antibody

    Also known as: MOR202

  • OtherPlacebo

    Placebo comparator

07

What researchers measure

Primary outcomes

  1. Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9

    Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR was estimated based on mixed effects model for repeated measure (MMRM) model. Least squares (LS) mean and standard error (SE) were reported. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.

    Time frame: Baseline, Month 9

Secondary outcomes

  1. Integrative Analysis of Several Endpoints: Percent Change From Baseline in Immunoglobulin A (IgA) Concentration by Predose Serum Concentration (Ctrough) Group

    All felzartamab and placebo-treated participants with evaluable IgA data and felzartamab serum concentrations (in felzartamab-treated participants only) were divided into exposure quartiles using the sum of measurable felzartamab Ctrough values up to 9 months after the first dose. Percent change from baseline in IgA concentration in these participants was summarized as per each serum concentration quartile.

    Time frame: Up to 9 months

  2. Integrative Analysis of Several Endpoints: Maximum Serum Concentrations (Cmax) as Per the Infusion-Related Reactions (IRRs) After the First Dose

    All participants with evaluable maximum felzartamab concentrations after the first dose were included in the analysis. Cmax values were assessed by infusion-related reaction status after the first dose.

    Time frame: Up to 1 week

  3. Part 1: Relative Change From Baseline in UPCR in 24-hour Urine at Months 3, 6, 12, 18 and 24

    Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR will be estimated based on an MMRM model. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.

    Time frame: Baseline, Months 3,6,12,18 and 24

  4. Part 1: Number of Participants With Complete Response (CR) at Months 3, 6, 9, 12, 18 and 24

    CR was defined as the reduction of proteinuria to less than 0.3 g/g UPCR, serum albumin within the reference range of the central laboratory and stable estimated glomerular filtration rate (eGFR) (at least 80% of value at baseline visit).

    Time frame: Months 3,6,9,12,18 and 24

  5. Part 1: Percentage of Participants With Response at Months 3, 6, 9, 12, 18 and 24

    Response was defined as reduction of proteinuria to below 0.6 g/g (UPCR) and stable eGFR (at least 80% of value at baseline visit), but not CR.

    Time frame: Months 3,6,9,12,18 and 24

  6. Part 1: Albumin-Creatinine Ratio (ACR) at Months 6, 9, 12, 18 and 24

    Time frame: Months 6, 9,12,18 and 24

  7. Part 1: Duration of Response

    Duration of response was defined as date of 1st observation of progressive disease minus date of 1st observation of response+1 day. Duration of response was estimated by Kaplan Meier method.

    Time frame: Up to 2 years

  8. Part 1: Time to Response

    Time to response was defined as date of 1st observation of response minus date of randomization+1 day. Time to response was estimated by Kaplan Meier method.

    Time frame: Up to 2 years

  9. Change From Baseline in eGFR Over Time

    eGFR was calculated as per the chronic kidney disease epidemiology collaboration (CKD-EPI) equation. eGFR =141×min(Scr/κ, 1)α×max(Scr κ,1)-1.209×0.993Age ×1.018\[if female\]×1.159 \[if black\] where: * Scr is serum creatinine in μmol/L, * κ is 61.9 for females and 79.6 for males, * α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1 eGFR as a measure of kidney function. eGFR was calculated in terms of milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). A numerically smaller negative change in eGFR indicates a slowing in kidney disease progression.

    Time frame: Baseline, Months 3,6,9,12,15,18, and 24

  10. Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)

    TEAEs were defined as any AEs reported after the start of trial treatment until 28 days after the last trial treatment, defined as the treatment-emergent period. TESAEs were TEAEs that met the following criteria: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.

    Time frame: From the first dose until 28 days after last dose of study drug (up to 191 days)

  11. Serum Concentrations of Felzartamab Over Time

    Time frame: Predose and 30 minutes post-dose on Days 1, 15, 29; predose on Days 8, 57, 85, 113, 141; Post Treatment Days 169 and 267

  12. Percentage of Participants With Anti- Felzartamab Antibodies

    Blood samples were collected for measurement of anti-felzartamab antibodies in the serum. Number of participants with Anti-drug antibody (ADA) status positive/negative was summarized.

    Time frame: From the first dose up to the end of the study (up to 2 years)

08

Results

Posted Apr 28, 2026

Participant flow

Participants were enrolled at investigative sites in Belgium, Bulgaria, Czechia, Georgia, Germany, Japan, Republic of Korea, Malaysia, Philippines, Serbia, Spain, Taiwan, Ukraine, and the United States from 31 August 2021 to 06 May 2024.

Participant flow — Overall Study
MilestonePart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
Started121211136
Completed10119126
Not completed21210
Withdrew: Investigator decision10000
Withdrew: Requires prohibited medication00110
Withdrew: Withdrawal of consent11100

Outcome measures

PrimaryPart 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9

Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR was estimated based on mixed effects model for repeated measure (MMRM) model. Least squares (LS) mean and standard error (SE) were reported. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.

Time frame:
Baseline, Month 9
Reported as:
Least squares mean · gram per gram (g/g)
Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9
gram per gram (g/g)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Part 1: Relative Change From Baseline in Urine Protein to Creatinine Ratio (UPCR) in 24-hour Urine at Month 9-24.7 ± 19.43-16.5 ± 19.41-30.6 ± 21.72-38.5 ± 16.60
Statistical analysis
  • Part 1: Placebo vs Part 1: Felzartamab Dosing Arm M1 · MMRM · p = 0.6837 · Geometric ls mean ratio: 1.11 · 95% CI 0.67 to 1.84Geometric mean ratio of UPCR at post baseline over baseline between Part 1: Felzartamab M1 to Part 1: Placebo.
  • Part 1: Placebo vs Part 1: Felzartamab Dosing Arm M2 · MMRM · p = 0.7599 · Geometric ls mean ratio: 0.92 · 95% CI 0.54 to 1.57Geometric mean ratio of UPCR at post baseline over baseline between Part 1: Felzartamab M2 to Part 1: Placebo.
  • Part 1: Placebo vs Part 1: Felzartamab Dosing Arm M3 · MMRM · p = 0.4165 · Geometric ls mean ratio: 0.82 · 95% CI 0.49 to 1.35Geometric mean ratio of UPCR at post baseline over baseline between Part 1: Felzartamab M3 to Part 1: Placebo.
SecondaryIntegrative Analysis of Several Endpoints: Percent Change From Baseline in Immunoglobulin A (IgA) Concentration by Predose Serum Concentration (Ctrough) Group

All felzartamab and placebo-treated participants with evaluable IgA data and felzartamab serum concentrations (in felzartamab-treated participants only) were divided into exposure quartiles using the sum of measurable felzartamab Ctrough values up to 9 months after the first dose. Percent change from baseline in IgA concentration in these participants was summarized as per each serum concentration quartile.

Time frame:
Up to 9 months
Reported as:
Mean · percent change
Integrative Analysis of Several Endpoints: Percent Change From Baseline in Immunoglobulin A (IgA) Concentration by Predose Serum Concentration (Ctrough) Group
percent changeAll Felzartamab and Placebo-Treated Participants
Serum Concentration 0-180 µg/mL-6.12 ± 15.0
Serum Concentration 180-370 µg/mL-14.1 ± 15.6
Serum Concentration 370-850 µg/mL-19.7 ± 22.7
Serum Concentration >850 µg/mL-26.1 ± 10.1
SecondaryIntegrative Analysis of Several Endpoints: Maximum Serum Concentrations (Cmax) as Per the Infusion-Related Reactions (IRRs) After the First Dose

All participants with evaluable maximum felzartamab concentrations after the first dose were included in the analysis. Cmax values were assessed by infusion-related reaction status after the first dose.

Time frame:
Up to 1 week
Reported as:
Mean · µg/mL
Integrative Analysis of Several Endpoints: Maximum Serum Concentrations (Cmax) as Per the Infusion-Related Reactions (IRRs) After the First Dose
µg/mLAll Felzartamab-Treated Participants
Cmax in Participants With IRR445 ± 198
Cmax in Participants Without IRR367 ± 131
SecondaryPart 1: Relative Change From Baseline in UPCR in 24-hour Urine at Months 3, 6, 12, 18 and 24

Proteinuria is high levels of protein in the urine and is measured by UPCR. Relative change in UPCR will be estimated based on an MMRM model. The reference proteinuria value before start of treatment is defined as the mean of the values determined at screening and prior to baseline (visit 2) predose (UPCR from 24h urine). Negative change from baseline indicates less proteinuria.

Time frame:
Baseline, Months 3,6,12,18 and 24
Reported as:
Least squares mean · g/g
Part 1: Relative Change From Baseline in UPCR in 24-hour Urine at Months 3, 6, 12, 18 and 24
g/gPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Change at Month 3-18.0 ± 13.09-7.5 ± 13.47-35.1 ± 17.06-35.5 ± 14.57
Change at Month 6-12.8 ± 20.85-29.3 ± 20.07-44.5 ± 23.32-43.9 ± 21.29
Change at Month 12-3.9 ± 19.521.1 ± 19.49-44.4 ± 21.81-38.2 ± 19.02
Change at Month 18-11.0 ± 23.40-24.9 ± 23.30-39.3 ± 25.54-48.3 ± 21.81
Change at Month 24-38.1 ± 33.67-15.3 ± 34.24-30.9 ± 38.03-48.6 ± 32.19
SecondaryPart 1: Number of Participants With Complete Response (CR) at Months 3, 6, 9, 12, 18 and 24

CR was defined as the reduction of proteinuria to less than 0.3 g/g UPCR, serum albumin within the reference range of the central laboratory and stable estimated glomerular filtration rate (eGFR) (at least 80% of value at baseline visit).

Time frame:
Months 3,6,9,12,18 and 24
Reported as:
Count of participants · Participants
Part 1: Number of Participants With Complete Response (CR) at Months 3, 6, 9, 12, 18 and 24
ParticipantsPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Month 30001
Month 60101
Month 90004
Month 120003
Month 180004
Month 241004
SecondaryPart 1: Percentage of Participants With Response at Months 3, 6, 9, 12, 18 and 24

Response was defined as reduction of proteinuria to below 0.6 g/g (UPCR) and stable eGFR (at least 80% of value at baseline visit), but not CR.

Time frame:
Months 3,6,9,12,18 and 24
Reported as:
Number · percentage of participants
Part 1: Percentage of Participants With Response at Months 3, 6, 9, 12, 18 and 24
percentage of participantsPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Month 38.39.1044.4
Month 609.1055.6
Month 99.1011.18.3
Month 129.1022.227.3
Month 180022.216.7
Month 24011.112.520.0
SecondaryPart 1: Albumin-Creatinine Ratio (ACR) at Months 6, 9, 12, 18 and 24
Time frame:
Months 6, 9,12,18 and 24
Reported as:
Mean · milligrams per gram (mg/g)
Part 1: Albumin-Creatinine Ratio (ACR) at Months 6, 9, 12, 18 and 24
milligrams per gram (mg/g)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Month 61.278 ± 0.81010.802 ± 0.46330.841 ± 0.79250.723 ± 1.0052
Month 91.053 ± 0.75170.830 ± 0.33780.834 ± 0.43910.948 ± 1.1494
Month 121.324 ± 0.77261.062 ± 0.50720.702 ± 0.43071.013 ± 1.5322
Month 181.305 ± 0.91550.729 ± 0.35010.822 ± 0.67150.827 ± 0.9789
Month 241.102 ± 0.89790.903 ± 0.50790.913 ± 0.60470.622 ± 0.9405
SecondaryPart 1: Duration of Response

Duration of response was defined as date of 1st observation of progressive disease minus date of 1st observation of response+1 day. Duration of response was estimated by Kaplan Meier method.

Time frame:
Up to 2 years
Reported as:
Median · days
Part 1: Duration of Response
daysPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Part 1: Duration of Response250 (78 to NA)140 (92 to NA)451 (NA to NA)188 (83 to NA)
SecondaryPart 1: Time to Response

Time to response was defined as date of 1st observation of response minus date of randomization+1 day. Time to response was estimated by Kaplan Meier method.

Time frame:
Up to 2 years
Reported as:
Median · days
Part 1: Time to Response
daysPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3
Part 1: Time to Response767 (300 to NA)NA (NA to NA)NA (NA to NA)176 (85.0 to NA)
SecondaryChange From Baseline in eGFR Over Time

eGFR was calculated as per the chronic kidney disease epidemiology collaboration (CKD-EPI) equation. eGFR =141×min(Scr/κ, 1)α×max(Scr κ,1)-1.209×0.993Age ×1.018\[if female\]×1.159 \[if black\] where: * Scr is serum creatinine in μmol/L, * κ is 61.9 for females and 79.6 for males, * α is -0.329 for females and -0.411 for males, min indicates the minimum of Scr/κ or 1, and max indicates the maximum of Scr/κ or 1 eGFR as a measure of kidney function. eGFR was calculated in terms of milliliter per minute per 1.73 meter square (mL/min/1.73 m\^2). A numerically smaller negative change in eGFR indicates a slowing in kidney disease progression.

Time frame:
Baseline, Months 3,6,9,12,15,18, and 24
Reported as:
Mean · mL/min/1.73 m^2
Change From Baseline in eGFR Over Time
mL/min/1.73 m^2Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
Change at Month 3-1.985 ± 7.59202.058 ± 4.98588.100 ± 18.12224.224 ± 8.31311.011 ± 6.3803
Change at Month 6-8.163 ± 12.4166-2.560 ± 6.61123.914 ± 12.46520.033 ± 12.75460.296 ± 7.1089
Change at Month 9-10.006 ± 9.3866-5.792 ± 7.32863.619 ± 11.2770-4.199 ± 15.8864-1.890 ± 2.9519
Change at Month 12-8.299 ± 11.1636-4.618 ± 7.9684-0.747 ± 15.3308-4.198 ± 9.1530-8.959 ± 5.6681
Change at Month 18-11.131 ± 9.7842-6.707 ± 8.49712.167 ± 11.0455-4.778 ± 11.7583—
Change at Month 24-9.550 ± 18.1470-7.394 ± 6.0913-3.342 ± 17.0161-6.210 ± 9.9485—
SecondaryNumber of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)

TEAEs were defined as any AEs reported after the start of trial treatment until 28 days after the last trial treatment, defined as the treatment-emergent period. TESAEs were TEAEs that met the following criteria: death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition.

Time frame:
From the first dose until 28 days after last dose of study drug (up to 191 days)
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Event (TEAE) and Treatment Emergent Serious Adverse Event (TESAE)
ParticipantsPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
TEAE6109113
TESAE01100
SecondarySerum Concentrations of Felzartamab Over Time
Time frame:
Predose and 30 minutes post-dose on Days 1, 15, 29; predose on Days 8, 57, 85, 113, 141; Post Treatment Days 169 and 267
Reported as:
Geometric mean · nanograms per milliliter (ng/mL)
Serum Concentrations of Felzartamab Over Time
nanograms per milliliter (ng/mL)Part 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
Day 1: Predose67.9 ± 143.554.6 ± 28.250.0 ± 0.050.0 ± 0.0
Day 1: 30 mins postdose204326.5 ± 3176.6320616.0 ± 56.2424347.7 ± 42.9355517.2 ± 21.9
Day 8: Predose123890.6 ± 34.3111734.3 ± 17.7119475.8 ± 29.9119280.5 ± 35.6
Day 15: Predose58680.3 ± 39.673299.3 ± 136.9242622.8 ± 14.9217362.3 ± 21.7
Day 15: 30 mins postdose479855.1 ± 27.8564030.0 ± 14.5726082.1 ± 18.0579946.2 ± 19.9
Day 29: Predose93782.5 ± 40.0142190.5 ± 28.3156053.1 ± 777.0339770.3 ± 39.1
Day 29: 30 mins postdose94110.3 ± 42.2471802.8 ± 29.7868596.5 ± 30.2696420.5 ± 22.7
Day 57: Predose5243.4 ± 1663.570569.7 ± 68.4126530.5 ± 40.1132181.4 ± 69.6
Day 85: Predose69.6 ± 153.021010.4 ± 3668.455920.7 ± 89.469524.7 ± 96.5
Day 113: Predose74.6 ± 199.2849.3 ± 2399.828697.5 ± 209.563543.2 ± 95.0
Day 141: Predose74.3 ± 194.450.0 ± 0.059744.8 ± 50.918172.1 ± 9900.0
Post Treatment Day 16964.8 ± 104.850.0 ± 0.048355.6 ± 109.335243.0 ± 194.3
Post Treatment Day 26772.8 ± 176.550.0 ± 0.050.0 ± 0.050.0 ± 0.0
SecondaryPercentage of Participants With Anti- Felzartamab Antibodies

Blood samples were collected for measurement of anti-felzartamab antibodies in the serum. Number of participants with Anti-drug antibody (ADA) status positive/negative was summarized.

Time frame:
From the first dose up to the end of the study (up to 2 years)
Reported as:
Count of participants · Participants
Percentage of Participants With Anti- Felzartamab Antibodies
ParticipantsPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
Positive (Post-baseline Visits)16331
Negative (Post-baseline Visits)1167105

Adverse events

Collected over From signing of informed consent up to the end of the study (up to 24 months). Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part 1: Placebo0/12 (0%)1/12 (8.3%)9/12 (75%)
Part 1: Felzartamab Dosing Arm M10/12 (0%)1/12 (8.3%)11/12 (91.7%)
Part 1: Felzartamab Dosing Arm M20/11 (0%)1/11 (9.1%)9/11 (81.8%)
Part 1: Felzartamab Dosing Arm M30/13 (0%)0/13 (0%)12/13 (92.3%)
Part 2: Japan Cohort0/6 (0%)0/6 (0%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
Infusion related reactionInjury, poisoning and procedural complications0/120/121/110/130/6
Tendon ruptureInjury, poisoning and procedural complications0/121/120/110/130/6
Dedifferentiated liposarcomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)1/120/120/110/130/6
Most frequent other events
Showing 10 of 136
Most frequent other events
EventPart 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan Cohort
COVID-19Infections and infestations3/124/122/116/132/6
NasopharyngitisInfections and infestations1/121/123/112/131/6
Upper respiratory tract infectionInfections and infestations0/122/122/111/130/6
ToothacheGastrointestinal disorders0/120/122/110/130/6
Infusion related reactionInjury, poisoning and procedural complications0/121/122/112/131/6
DizzinessNervous system disorders1/120/122/110/130/6
CellulitisInfections and infestations0/120/120/110/131/6
PharyngitisInfections and infestations0/120/120/110/131/6
Abdominal discomfortGastrointestinal disorders0/120/120/110/131/6
VomitingGastrointestinal disorders2/120/121/110/130/6

Baseline characteristics

All enrolled participants included all randomized participants from the full analysis set (FAS) plus all Japanese participants who were enrolled in Part 2. The FAS included participants randomized to Part 1 of the study.

Age, Continuous
Age, Continuous(years)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan CohortTotal
Mean39.6 ± 11.8447.4 ± 10.4135.1 ± 14.3139.2 ± 7.2051.7 ± 14.1941.6 ± 12.30
Sex: Female, Male
Sex: Female, Male(Participants)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan CohortTotal
Female3633318
Male96810336
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan CohortTotal
Race — White9699033
Race — American Indian or Alaska Native010001
Race — Asian3524620
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan CohortTotal
Ethnicity — Hispanic or Latino110204
Ethnicity — Not Hispanic or Latino11888641
Ethnicity — Not Reported023308
Ethnicity — Unknown010001
Urine Protein to Creatinine Ratio (UPCR)
Urine Protein to Creatinine Ratio (UPCR)(gram per gram (g/g))Part 1: PlaceboPart 1: Felzartamab Dosing Arm M1Part 1: Felzartamab Dosing Arm M2Part 1: Felzartamab Dosing Arm M3Part 2: Japan CohortTotal
Mean2.04 ± 1.1581.57 ± 0.7421.76 ± 0.8281.69 ± 1.3011.02 ± 0.3241.68 ± 0.999
09

Study locations

59 sites
  • FOMAT Medical Research - FOMAT - HyperCore - PPDS
    Oxnard, California 93030, United States
  • Amicis Research Center, Vacaville
    Vacaville, California 95687, United States
  • Mayo Clinic Hospital - Methodist Campus
    Rochester, Minnesota 55902, United States
  • MedResearch INC
    El Paso, Texas 79935, United States
  • Core Research Group
    Milton, Queensland 4064, Australia
  • Sunshine Hospital - Australia
    Saint Albans, Victoria, Australia
  • Imelda VZW
    Bonheiden, Antwerpen, Belgium
  • UZ Leuven Hospital
    Leuven, Vlaams Brabant 3000, Belgium
  • Regionaal Ziekenhuis Jan Yperman VZW
    Ieper, Belgium
  • CHU Sart Tilman Hospital
    Liège, 4000, Belgium
  • Diagnostic- Consultative Center Convex EOOD
    Sofia, Sofia-Grad 1680, Bulgaria
  • Medical Center Hera EOOD, Montana
    Montana, 3400, Bulgaria
  • Medical Center Hipokrat- N EOOD
    Plovdiv, 4000, Bulgaria
  • University Multiprofile Hospital for Active Treatment
    Stara Zagora, Bulgaria
  • Nemocnice AGEL Novy Jicin a.s
    Nový Jicín, Moravian-Silesian Region 741 01, Czechia
  • Eticka komise Fakultni nemocnice Olomouc
    Olomouc, Olomouc Region 775 20, Czechia
  • Fakultni nemocnice Kralovske Vinohrady Hospital
    Prague, Praha, Hlavní Mesto 10034, Czechia
  • Vseobecna Fakultni Nemocnice V Praze
    Prague, Praha, Hlavní Mesto 128 08, Czechia
  • JSC Evex Hospitals
    Tbilisi, 121, Georgia
  • L. Managadze National Center of Urology LTD
    Tbilisi, 144, Georgia
  • Tbilisi State Medical University's and Ingorokva's University Clinic of High Medical Technologies
    Tbilisi, 144, Georgia
  • Medizinische Hochschule Hannover
    Hanover, Lower Saxony 30625, Germany
  • Universitätsklinikum Essen
    Essen, North Rhine-Westphalia 45122, Germany
  • Universitätsmedizin der Johannes Gutenberg-Universität Mainz
    Mainz, Germany
  • National Hospital Organization Chibahigashi National Hospital
    Chiba, Chiba 260-0801, Japan
  • Hokkaido University Hospital
    Sapporo, Hokkaidô 060-8648, Japan
  • Hospital of the University of Occupational and Environmental Health, Japan
    Kitakyushu-Shi, Hukuoka 807-8556, Japan
  • Kurume University Hospital
    Kurume-Shi, Hukuoka 830-0011, Japan
  • Fukushima Medical University Hospital
    Fukushima, Hukusima 960-1295, Japan
  • JCHO Sendai Hospital
    Sendai, Miyagi 981-3205, Japan
  • Japanese Red Cross Ashikaga Hospital
    Ashikaga-Shi, Tochigi 326-0843, Japan
  • Juntendo University Hospital
    Bunkyō-Ku, Tokyo 113-8431, Japan
  • Osaka University Hospital
    Suita-Shi, Ôsaka 565-0871, Japan
  • University Malaya Medical Centre
    Pantai, Malaysia
  • St Frances Cabrini Medical Center and Cancer Institute
    Santo Tomas, Batangas 4234, Philippines
  • Clinical Centre of Vojvodina
    Novi Sad, Vojvodina 21000, Serbia
  • Clinical Hospital Center Bezanijska Kosa
    Belgrade, 11080, Serbia
  • Clinical Hospital Centar Zvezdara
    Belgrade, Serbia
  • General Hospital Krusevac
    Kruševac, 37000, Serbia
  • University Clinical Center Nis
    Niš, 18000, Serbia
  • Seoul National University Bundang Hospital
    Seongnam, Gyeonggido 13620, South Korea
  • Ajou University Hospital
    Suwon, Gyeonggido 16499, South Korea
  • Konkuk University Medical Center
    Seoul, Seoul Teugbyeolsi 5030, South Korea
  • The Catholic University of Korea, Uijeongbu St. Mary's Hospital
    Uijeongbu-si, South Korea
  • Fundacio Puigvert
    Badalona, 8025, Spain
  • Hospital Universitario Germans Trias i Pujol
    Badalona, 8916, Spain
  • Hospital del Mar
    Barcelona, 8003, Spain
  • Hospital Universitario Vall d'Hebron - PPDS
    Barcelona, 8035, Spain
  • Hospital Clinic de Barcelona
    Barcelona, 8036, Spain
  • Hospital Universitari de Girona Dr Josep Trueta
    Girona, Spain
  • Hospital Universitari Arnau de Vilanova
    Lleida, 25198, Spain
  • Hospital Ruber Juan Bravo (Grupo Quironsalud)
    Madrid, Spain
  • Taipei Medical University Shuang Ho Hospital
    New Taipei City, 23561, Taiwan
  • Taichung Veterans General Hospital
    Taichung, 407, Taiwan
  • Far Eastern Memorial Hospital
    Taipei, 220, Taiwan
  • Municipal Non-profit Enterprise Ternopil Regional Clinical Hospital of Ternopil Regional Council
    Ternopil, Ternopil Oblast 46002, Ukraine
  • Communal Nonprofit Enterprise "Kyiv City Center of Nephrology and Dialysis"
    Kyiv, Ukraine
  • State Institution Institute of Nephrology of NAMS of Ukraine
    Kyiv, Ukraine
  • Municipal Nonprofit Enterprise Zaporizhzhia Regional Clinical Hospital Zaporizhzhia Regional Council
    Zaporizhzhya, 69600, Ukraine
10

References and documents

Publications

  • Floege J, Lafayette R, Barratt J, Schwartz B, Manser PT, Patel UD, Shah M, Kivman L, Faulhaber N, Kraft T, Thakur A, Hartle S, Barbour SJ. Randomized, double-blind, placebo-controlled phase 2a study assessing the efficacy and safety of felzartamab for IgA nephropathy. Kidney Int. 2025 Oct;108(4):695-706. doi: 10.1016/j.kint.2025.05.028. Epub 2025 Jun 26. PubMed 40581166 ↗
  • Ahmad SB, Jefferson JA. Targeting B Cells and Plasma Cells in Glomerular Disease. J Am Soc Nephrol. 2025 Jun 4;36(9):1844-1857. doi: 10.1681/ASN.0000000772. PubMed 40465397 ↗
  • Mayer KA, Budde K, Diebold M, Halloran PF, Bohmig GA. Targeting CD38 in Antibody-Mediated Rejection. Transpl Int. 2025 May 15;38:14343. doi: 10.3389/ti.2025.14343. eCollection 2025. PubMed 40444214 ↗
  • Tunnicliffe DJ, Reid S, Craig JC, Samuels JA, Molony DA, Strippoli GF. Non-immunosuppressive treatment for IgA nephropathy. Cochrane Database Syst Rev. 2024 Feb 1;2(2):CD003962. doi: 10.1002/14651858.CD003962.pub3. PubMed 38299639 ↗
  • El Karoui K, Fervenza FC, De Vriese AS. Treatment of IgA Nephropathy: A Rapidly Evolving Field. J Am Soc Nephrol. 2024 Jan 1;35(1):103-116. doi: 10.1681/ASN.0000000000000242. Epub 2023 Sep 29. PubMed 37772889 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Yes — In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/

Data sharing details ↗ · vivli.org

11

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2021 to primary completion in Feb 2023, 17 months.

Results were first posted in Apr 2026, 3 years 2 months after primary completion. A results delay was requested in Feb 2024.

Of 41 phase 2 interventional studies under Glomerulonephritis, IGA, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 50. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2021
First posted
Oct 4, 2021
StartActual
Aug 31, 2021
Primary completionActual
Feb 6, 2023
CompletionActual
May 6, 2024
Results delay requested
Feb 2, 2024
Results first posted
Apr 28, 2026
Last update
Apr 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 28, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT05065970
Responsible party
Sponsor
First posted
Oct 4, 2021
Start date
Aug 31, 2021
Primary completion
Feb 6, 2023
Completion
May 6, 2024
Results posted
Apr 28, 2026
Last update
Apr 28, 2026

Study contacts

Medical Director
study director · HI-Bio, A Biogen Company

Oversight

FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Felzartamab

Start the discussion